Patent: 7,879,328
Summary for Patent: 7,879,328
| Title: | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| Abstract: | The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. |
| Inventor(s): | Steven M. Ruben, Gil H. Choi, Tristan Vaughan, David Hilbert |
| Assignee: | Human Genome Sciences Inc |
| Application Number: | US11/054,515 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,879,328
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | BENLYSTA | belimumab | For Injection | 125370 | March 9, 2011 | 7,879,328 | 2025-02-10 |
| Glaxosmithkline Llc | BENLYSTA | belimumab | Injection | 761043 | July 20, 2017 | 7,879,328 | 2025-02-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
